Cathy Eng, MD, FACP, FASCO, discusses future research efforts in the adjuvant setting for colorectal cancer.
Cathy Eng, MD, FACP, FASCO, David H. Johnson Chair in Surgical and Medical Oncology; co-leader of the Gastrointestinal (GI) Cancer Research Program; professor of medicine in hematology and oncology; co-director of GI Oncology; vice chair of the SWOG GI Committee; and director of the VICC Young Adult Cancers Initiative at Vanderbilt-Ingram Cancer Center, discusses future research efforts in the adjuvant setting for colorectal cancer (CRC).
It's unlikely that additional studies will examine the role of adjuvant chemotherapy in CRC, according to Eng. Rather, more research efforts will examine the role of circulating tumor DNA (ctDNA). For example, the COBRA study, which has just recently opened within the past few months, is evaluating how well ctDNA testing in the blood works in predicting treatment for patients with stage IIA colon cancer following surgery.
Eligible patients with CRC should participate in this trial, Eng concludes.